Core Viewpoint - Citigroup's stock has experienced a significant decline, falling approximately 20% from its highs, which is notably worse than the S&P 500 index's decline of over 10% [1][2] Group 1: Stock Performance - Citigroup's shares have rebounded somewhat but remain down about 16%, compared to the S&P 500's decline of roughly 7.5% [2] - Between mid-September 2024 and its recent sell-off, Citigroup's stock gained over 40%, and it is still up more than 20% since that time despite the recent downturn [3] Group 2: Valuation Metrics - Citigroup's current price-to-sales (P/S) ratio is approximately 1.7, compared to a five-year average of just under 1.5 [5] - The price-to-earnings (P/E) ratio stands at 12, against a longer-term average of about 8.2 [5] - The price-to-book (P/B) ratio is 0.7, in contrast to a five-year average of around 0.6 [5] Group 3: Historical Context - Citigroup's recent decline is relatively minor compared to other sell-offs over the past decade, suggesting that the current drop may not be as significant [6] - There is a possibility that Citigroup's stock could decline further based on its current valuation metrics [6] Group 4: Investment Considerations - Despite the recent price drop, Citigroup does not appear to be a compelling buy for value-oriented investors, as it has not fallen to a level that would warrant immediate purchase [7]

Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100% increase year-over-year, with a 6.7% upward revision in estimates over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31% increase from the previous year, with a 6.9% upward revision [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), indicating a positive outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3% increase, while the next fiscal year's estimate is $611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1% year-over-year increase, and an EPS of $0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].

Core Viewpoint - Arch Capital Group (ACGL) has been gaining attention as one of the most searched stocks, with its performance influenced by various fundamental factors [1][2]. Earnings Estimates - For the current quarter, Arch Capital is expected to report earnings of $1.59 per share, reflecting a year-over-year decline of -35.1%, with the Zacks Consensus Estimate decreasing by -11.3% over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year stands at $8.16, indicating a year-over-year change of -12.1%, with a recent adjustment of -4.4% [5]. - For the next fiscal year, the consensus earnings estimate is $9.71, showing a year-over-year increase of +19%, with a slight change of -0.6% over the past month [6]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.56 billion, representing a year-over-year increase of +21.1% [9]. - For the current fiscal year, the revenue estimates are $18.94 billion and $20.62 billion, indicating changes of +13.9% and +8.9%, respectively [9]. Last Reported Results - In the last reported quarter, Arch Capital achieved revenues of $4.55 billion, a year-over-year increase of +23.8%, and an EPS of $2.26, down from $2.49 a year ago [11]. - The reported revenues exceeded the Zacks Consensus Estimate of $4.28 billion by +6.14%, while the EPS surprise was +22.16% [11]. - The company has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times during this period [11]. Valuation - Arch Capital is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [15]. - The evaluation of valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) is essential for determining the stock's fair value [13][14].

General Mills Stock Forecast Today12-Month Stock Price Forecast:$67.5314.01% Upside HoldBased on 18 Analyst RatingsCurrent Price$59.23High Forecast$82.00Average Forecast$67.53Low Forecast$58.00General Mills Stock Forecast DetailsGeneral Mills NYSE: GIS isn’t an exciting stock, and its business faces headwinds, but it is fundamentally sound, investing in a turnaround and trading at historically low valuations. The stock is valued at only 14x earnings in early 2025, well below the 18x 10-year average while of ...

Core Viewpoint - ASML has been trending in stock searches, prompting analysis of factors influencing its stock performance in the near future [1] Earnings Estimate Revisions - For the current quarter, ASML is expected to post earnings of $6.12 per share, reflecting an increase of +81.1% year-over-year, with a consensus estimate change of +1.6% over the last 30 days [5] - The consensus earnings estimate for the current fiscal year is $25.37, indicating a +21.9% change from the previous year, with a +0.8% change in the last 30 days [5] - For the next fiscal year, the consensus estimate is $29.55, showing a +16.5% change year-over-year, with a +1% change over the past month [6] Revenue Growth Projections - The consensus sales estimate for the current quarter is $8.08 billion, representing a +40.7% year-over-year change [9] - The sales estimates for the current and next fiscal years are $34.34 billion and $37.97 billion, indicating changes of +12.4% and +10.6%, respectively [9] Last Reported Results - ASML reported revenues of $9.88 billion in the last quarter, a +26.8% year-over-year increase, with an EPS of $7.30 compared to $5.60 a year ago [10] - The reported revenues exceeded the Zacks Consensus Estimate of $9.76 billion by +1.2%, and the EPS surprise was +1.67% [11] - ASML has consistently beaten consensus EPS and revenue estimates in the last four quarters [11] Valuation - ASML is graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [15] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether ASML's stock is overvalued, fairly valued, or undervalued [13][14] Overall Assessment - The Zacks Rank 3 suggests ASML may perform in line with the broader market in the near term, despite the market buzz [16]

Core Viewpoint - Starbucks is facing challenges in growth despite its strong brand and recent leadership changes, with concerns about its stock valuation amidst ongoing economic uncertainties [1][4][7]. Group 1: Company Performance - Starbucks has experienced a slowdown in growth, with negative same-store sales for four consecutive quarters, indicating struggles in generating revenue from existing locations [3][4]. - The company appointed CEO Brian Niccol from Chipotle Mexican Grill to help turn around its business, but the effectiveness of these efforts is still uncertain [2][4]. - Recent earnings reports show that overall growth rates have not been impressive, raising concerns among investors [3][4]. Group 2: Stock Valuation - The stock has rallied over 20% in the past six months, reaching a 52-week high of $117.46, but this increase may have led to an overvaluation given the company's current challenges [2][5]. - Investors are currently paying 37 times the trailing earnings for Starbucks stock, which is considered expensive for a company struggling to generate growth [5][6]. - There is a perception that the stock may be priced with too much optimism, as the company has not demonstrated a clear path to revenue growth that justifies its high valuation [7][8].

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.67 per share, reflecting a year-over-year increase of +19.6% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.85, indicating a +13.6% change from the previous year, with a +2.7% increase in estimates over the last 30 days [5] - For the next fiscal year, the consensus estimate is $3.23, showing a +13.2% change from the prior year, with a +2.2% increase in estimates over the past month [6] - The Zacks Rank for Boston Scientific is 2 (Buy), suggesting a positive outlook based on recent earnings estimate revisions [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.56 billion, indicating a year-over-year increase of +18.2% [9] - For the current fiscal year, the sales estimate is $19.05 billion, reflecting a +13.8% change, while the next fiscal year's estimate is $21 billion, indicating a +10.2% change [9] Last Reported Results and Surprise History - Boston Scientific reported revenues of $4.56 billion in the last quarter, representing a +22.4% year-over-year change [10] - The reported EPS was $0.70, compared to $0.55 a year ago, with a revenue surprise of +3.52% and an EPS surprise of +7.69% [11] - The company has consistently beaten consensus EPS and revenue estimates over the last four quarters [11] Valuation - Boston Scientific has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15]

Core Viewpoint - Vital Farms (VITL) has experienced a significant decline in stock performance, returning -18.3% over the past month, contrasting with the S&P 500's -4.1% and the Zacks Food - Miscellaneous industry's gain of +5.3% [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.28 per share, reflecting a year-over-year decrease of -34.9%, with a recent change of -27.7% in the estimate [4] - For the current fiscal year, the consensus earnings estimate is $1.24, indicating a +5.1% change from the previous year, with a slight increase of +0.3% over the last 30 days [4] - The next fiscal year's consensus earnings estimate is $1.52, suggesting a +22.3% increase from the prior year, although it has decreased by -2.6% recently [5] Revenue Growth Projections - The consensus sales estimate for the current quarter is $163.5 million, representing a year-over-year increase of +10.5% [8] - For the current fiscal year, the sales estimate is $741.03 million, indicating a +22.2% change, while the next fiscal year's estimate of $875.35 million reflects an +18.1% change [8] Last Reported Results and Surprise History - In the last reported quarter, Vital Farms achieved revenues of $165.99 million, a +22.2% increase year-over-year, with an EPS of $0.23 compared to $0.17 a year ago [9] - The reported revenues exceeded the Zacks Consensus Estimate of $160.23 million by +3.6%, and the EPS surprise was +53.33% [10] - The company has consistently beaten consensus EPS and revenue estimates over the past four quarters [10] Valuation - Vital Farms holds a Zacks Rank of 3 (Hold), indicating it may perform in line with the broader market in the near term [6][15] - The company is graded C in the Zacks Value Style Score, suggesting it is trading at par with its peers [14]

Core Viewpoint - Agnico Eagle Mines (AEM) has shown a positive stock performance of +1% over the past month, contrasting with the Zacks S&P 500 composite's -4.1% change, indicating potential resilience in the gold mining sector [1] Earnings Estimates Revisions - Agnico is expected to report earnings of $1.05 per share for the current quarter, reflecting a year-over-year increase of +38.2%, with a recent consensus estimate change of +9.2% [4] - For the current fiscal year, the consensus earnings estimate stands at $4.70, indicating a year-over-year change of +11.1%, although this estimate has decreased by -1.2% over the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.13, suggesting a decline of -12.1% from the previous year, with a slight increase of +0.5% in the last month [5] Revenue Growth Forecast - The consensus sales estimate for Agnico is $2.24 billion for the current quarter, representing a year-over-year growth of +22.4% [8] - For the current fiscal year, revenue estimates are $9.22 billion, indicating a growth of +11.3%, while the next fiscal year's estimate of $8.9 billion reflects a decline of -3.5% [8] Last Reported Results and Surprise History - In the last reported quarter, Agnico achieved revenues of $2.22 billion, marking a year-over-year increase of +26.6%, with an EPS of $1.26 compared to $0.57 a year ago [9] - The reported revenues exceeded the Zacks Consensus Estimate of $2.1 billion by +6.03%, and the EPS surprise was +7.69% [10] - Agnico has consistently beaten consensus EPS and revenue estimates in the last four quarters [10] Valuation - Agnico holds a Zacks Rank 3 (Hold), indicating it may perform in line with the broader market in the near term [6][15] - The Zacks Value Style Score grades Agnico as C, suggesting it is trading at par with its peers [14]

Core Viewpoint - Airbnb's stock has shown a strong performance recently, returning +10% over the past month, contrasting with the S&P 500's -4.1% and the Leisure and Recreation Services industry's -6% [1] Earnings Estimates Revisions - For the current quarter, Airbnb is expected to report earnings of $0.26 per share, reflecting a decrease of -36.6% year-over-year, with a +9.7% increase in the Zacks Consensus Estimate over the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $4.31, indicating a year-over-year increase of +4.9%, with a slight change of +0.4% in the last 30 days [4] - For the next fiscal year, the consensus estimate is $4.98, representing a +15.5% increase from the previous year, with a +1.2% change over the past month [5] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $2.27 billion, indicating a year-over-year growth of +6% [8] - For the current fiscal year, the revenue estimates are $12.22 billion and $13.54 billion, reflecting changes of +10.1% and +10.8%, respectively [8] Last Reported Results and Surprise History - In the last reported quarter, Airbnb generated revenues of $2.48 billion, marking an +11.8% year-over-year increase, with an EPS of $0.73 compared to $0.76 a year ago [9] - The reported revenues exceeded the Zacks Consensus Estimate of $2.42 billion by +2.47%, and the EPS surprise was +25.86% [10] - Over the last four quarters, Airbnb surpassed consensus EPS estimates twice and revenue estimates three times [10] Valuation - Airbnb is graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [14]